


Effect of Folate Targeted Immunotherapy on the Survival of Mice with Lung Tumor Implants







Tumor Growth Curve*



Effect of Cytokine Combinations on Folate-Targeted Immunotherapy*



Immunotherapy Update*








Fig. 7

The Effect of Mouse NK Cell Depletion on Folate Targetd Immunotherapy*



Development of Cellular Immunity against the Parental M109 Tumor Cells



-o- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/day), and IFN- α (25,000 U/day)

--- 50X +FEFITC --- 1X+FEFITC - 4 − 100X -a-10X -0-1X the IL-2 dosing effect on i.p. M109 Tumor FEFITC-Targeted Immunotherapy: Day Post Tumor Implantation 30 35 40 45 50 15 20 25 9. 75-50-25survival %

Fig. 10

IFN-α Further Enhances IL-2-augmented Immunotherapeutic Effect of FEFITC in Mice with Pre-existing Anti-FITC Antibody







Fig. 11

Effect of Depletion of CD8+ T cells on Folate-Targeted Immunotherapy



The Effect of a Third Cytokine, GM-CSF on Folate-Targeted Immunotherapy








Fig. 14

Folate-Targeted Immunotherapy: the effect of DNP as a hapten against i.p. M109 Tumor





Fig. 15

Synergistic Effect of FEFITC and IFN- α against Intraperitoneal M109 Tumor



Folate-DNP Further Enhanced the Therapeutic Effect of a High Dose Combination of IL-2 and IFN-α in Mice with Pre-existing Anti-DNP Antibody




Fig. 17